|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Fumapharm_AG
gptkb:Zymeworks
gptkb:Acorda_Therapeutics
gptkb:CureVac_AG
OncoImmune
Sage Therapeutics
Alynylam_Pharmaceuticals
Neurimmune_AG
Therapix_Biosciences
|
|
gptkbp:advertising
|
Michael_Ehlers
|
|
gptkbp:CEO
|
gptkb:Michel_Vounatsos
|
|
gptkbp:clinicalTrials
|
Alzheimer's disease
Multiple sclerosis
Spinal muscular atrophy
|
|
gptkbp:employees
|
7,000 (2020)
|
|
gptkbp:founded
|
1978
|
|
gptkbp:founder
|
gptkb:M._A._(Marty)_Dyer
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Biogen Idec Ltd.
|
|
gptkbp:industry
|
Biotechnology
|
|
gptkbp:operates_in
|
gptkb:Jim_Mullen
|
|
gptkbp:partnerships
|
gptkb:Samsung_Bioepis
gptkb:Ionis_Pharmaceuticals
|
|
gptkbp:products
|
gptkb:Tecfidera
gptkb:Spinraza
gptkb:Avonex
gptkb:Tysabri
|
|
gptkbp:research
|
Alfred_Sandrock
|
|
gptkbp:research_focus
|
cancer
genetic disorders
neurodegenerative diseases
rare diseases
autoimmune diseases
infectious diseases
pain management
neuromuscular diseases
psychiatric disorders
neuroinflammatory diseases
|
|
gptkbp:revenue
|
$11.4 billion (2020)
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
gptkb:BIIB
|
|
gptkbp:subsidiary
|
gptkb:Ionis_Pharmaceuticals
|
|
gptkbp:website
|
www.biogen.com
|